
Day Zero receives $8.2M to speed development of infectious disease diagnostic
October 21 2022
Day Zero receives $8.2M from CARB-X to speed development of infectious disease diagnostics.
Read More
Day Zero Diagnostics secures additional $8.2M from CARB-X
October 20 2022
Additional CARB-X funding supports the transition into product development of the firm's whole-genome sequencing and machine learning-based approach to antimicrobial resistance profiling.
Read More
Day Zero Diagnostics at EADA 2021: A better way to diagnose and treat sepsis is on the horizon
January 5 2022
Learn how we are predicting antimicrobial susceptibility directly from blood using whole-genome sequencing with Day Zero Diagnostic's Scientific Co-founder, Melis Anahtar, MD, Phd.
Read More
Diagnosis On Day Zero
January 4 2022
Day Zero Diagnostics was featured in AACC's December issue of "Clinical Laboratory News", highlighting our work around whole genome sequencing and machine learning for rapid diagnosis of infections directly from blood.
Read More
Day Zero Diagnostics wins 2021 AACC disruptive tech award
September 29 2021
Day Zero is proud to have been selected for the Disruptive Technology Award from AACC
Read More
Unbundling LabCorp: How Traditional Lab Testing Is Being Disrupted
December 16 2020
Day Zero is honored to be included in this group of innovative companies disrupting traditional lab testing
Read More